2016/02/26 by Davide Corti, John Misasi, Sabue Mulangu +28 · 2 citations
Medicine · #Viral Infections and Outbreaks Research #Viral Infections and Vectors #Hepatitis B Virus Studies
paper · doi:10.1126/science.aad5224
openalex publication_date 2016/02/26 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to 90%. There is no licensed treatment or vaccine against the virus, underscoring the need for efficacious countermeasures. We ascertained that a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating antibodies against the Ebola virus surface glycoprotein for more than a decade after infection. From this survivor we isolated monoclonal antibodies (mAbs) that neutralize recent and previous outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro. Strikingly, monotherapy with mAb114 protected macaques when given as late as 5 days after challenge. Treatment with a single human mAb suggests that a simplified therapeutic strategy for human Ebola infection may be possible.